申请人:Novartis AG
公开号:EP2177518A1
公开(公告)日:2010-04-21
3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4-substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula I,
wherein the symbols have the meanings defined in the specification.
3,4-取代的哌啶化合物,这些化合物用于温血动物的诊断和治疗,特别是用于治疗依赖于肾素活性的疾病(=失调);该类化合物用于制备治疗依赖于肾素活性的疾病的药物制剂;公开了该类化合物在治疗依赖肾素活性的疾病中的用途;包含3,4-取代的哌啶化合物的药物制剂,和/或包括施用3,4-取代的哌啶化合物的治疗方法,3,4-取代的哌啶化合物的制造方法,以及新型中间体及其合成的部分步骤。3,4-二取代哌啶化合物具有式 I、
其中符号具有本说明书中定义的含义。